Lung injury after cardiopulmonary bypass:Alternative treatment prospects  

作　　者：Xue-Mei Zheng Zhuo Yang Guang-Li Yang Yan Huang Jie-Ru Peng Meng-Jun Wu 

机构地区：[1]School of Medicine,University of Electronic Science and Technology of China,Chengdu 610000,Sichuan Province,China [2]Department of Pharmacy,Chengdu Women’s and Children’s Central Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610000,Sichuan Province,China [3]Department of Medical Administration,Chengdu Women’s and Children’s Central Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610000,Sichuan Province,China [4]National Institute of Drug Clinical Trial,Chengdu Women’s and Children’s Central Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610000,Sichuan Province,China [5]Department of Medical Records Statistics,Chengdu Women’s and Children’s Central Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610000,Sichuan Province,China [6]Department of Anesthesiology,The Affiliated Hospital,School of Medicine,Chengdu Women's and Children's Central Hospital,University of Electronic Science and Technology,Chengdu 610000,Sichuan Province,China

出　　处：《World Journal of Clinical Cases》2022年第3期753-761,共9页世界临床病例杂志

摘　　要：Although the lung injury caused by cardiopulmonary bypass(CPB)has been extensively investigated,the incidence and mortality of lung injury after CPB remain a prominent clinical problem.The poor outcome has been attributed to multifactorial etiology,including the systemic inflammatory response and ischemia reperfusion(I/R)injury during CPB.Lung injury after CPB is a complex pathophysiological process and has many clinical manifestations of mild to severe disease.Which is associated with prognosis.To alleviate this lung injury,interventions that address the pathogenesis are particularly important.This review summarizes the pathogenesis,mechanism and treatment options of lung injury after CPB,such as lung protection with intralipid.

关 键 词：Cardiopulmonary bypass Lung injury PATHOGENESIS Treatment INTRALIPID Systemic inflammatory response syndrome 

分 类 号：R563[医药卫生—呼吸系统]